Autocrine/paracrine erythropoietin signalling promotes JAK/STAT-dependent proliferation of human cervical cancer cells

被引:46
作者
Lopez, Tania V. [1 ]
Lappin, Terence R. J. [2 ]
Maxwell, Perry [2 ]
Shi, Zhanzhong [2 ]
Lopez-Marure, Rebeca [3 ]
Aguilar, Cecilia [1 ]
Rocha-Zavaleta, Leticia [1 ]
机构
[1] Univ Nacl Autonoma Mexico, Inst Invest Biomed, Dept Mol Biol & Biotechnol, Mexico City 04510, DF, Mexico
[2] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast BT7 1NN, Antrim, North Ireland
[3] Inst Nacl Cardiol Ignacio Chavez, Dept Biol Celular, Mexico City, DF, Mexico
关键词
cervical cancer; erythropoietin; JAK-STAT; proliferation; RECEPTOR EXPRESSION; CARCINOMA CELLS; UTERINE CERVIX; TUMOR-CELLS; NUDE-MICE; ACTIVATION; ERYTHROCYTOSIS; HYPOXIA; STAT3; ANTIBODIES;
D O I
10.1002/ijc.25935
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Erythropoietin (Epo) regulates erythropoiesis by binding to its receptor (EpoR) and promoting cell proliferation, differentiation and inhibition of apoptosis. Epo is widely used to treat cervical cancer-related anaemia. However, there are data suggesting that administration of Epo is associated with an increment in recurrence rate, and decreased disease-free and overall survival. In the present study, we investigated the expression of Epo and EpoR on cervical cancer cell lines. We observed that both EpoR and extracellular Epo are constitutively expressed in cervical cancer cells. Inhibition of either Epo or EpoR expression with siRNA attenuated cell proliferation, whereas addition of exogenous Epo led to a significant increase in cell growth, both in vitro and in vivo. Epo-induced proliferation was associated with the activation of JAK2, JAK3, STAT3 and STAT5 but not JAK1 and STAT1. Our results are consistent with the existence of a functional, endogenous Epo/EpoR system in cervical cancer with the capacity to activate the transduction of signals resulting in an increased proliferation potential.
引用
收藏
页码:2566 / 2576
页数:11
相关论文
共 40 条
[1]   Autocrine erythropoietin signaling inhibits hypoxia-induced apoptosis in human breast carcinoma cells [J].
Acs, G ;
Chen, M ;
Xu, XW ;
Acs, P ;
Verma, A ;
Koch, CJ .
CANCER LETTERS, 2004, 214 (02) :243-251
[2]   Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression [J].
Acs, G ;
Zhang, PJ ;
McGrath, CM ;
Acs, P ;
McBroom, J ;
Mohyeldin, A ;
Liu, SZ ;
Lu, HS ;
Verma, A .
AMERICAN JOURNAL OF PATHOLOGY, 2003, 162 (06) :1789-1806
[3]  
Belenkov AI, 2004, MOL CANCER THER, V3, P1525
[4]   EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer:: 2006 update [J].
Bokemeyer, C. ;
Aapro, M. S. ;
Courdi, A. ;
Foubert, J. ;
Link, H. ;
Osterborg, A. ;
Repetto, L. ;
Soubeyran, P. .
EUROPEAN JOURNAL OF CANCER, 2007, 43 (02) :258-270
[5]   Erythropoietin receptor expression in non-small cell lung carcinoma: A question of antibody specificity [J].
Brown, W. Mark ;
Maxwell, Perry ;
Graham, Alastair N. J. ;
Yakkundi, Anita ;
Dunlop, Elaine A. ;
Shi, Zhanzhong ;
Johnston, Patrick G. ;
Lappin, Terence R. J. .
STEM CELLS, 2007, 25 (03) :718-722
[6]   TYROSINE-343 IN THE ERYTHROPOIETIN RECEPTOR POSITIVELY REGULATES ERYTHROPOIETIN-INDUCED CELL-PROLIFERATION AND STAT5 ACTIVATION [J].
DAMEN, JE ;
WAKAO, H ;
MIYAJIMA, A ;
KROSL, J ;
HUMPHRIES, RK ;
CUTLER, RL ;
KRYSTAL, G .
EMBO JOURNAL, 1995, 14 (22) :5557-5568
[7]   Anti-Epo receptor antibodies do not predict Epo receptor expression [J].
Elliott, S ;
Busse, L ;
Bass, MB ;
Lu, H ;
Sarosi, I ;
Sinclair, AM ;
Spahr, C ;
Um, M ;
Van, G ;
Begley, CG .
BLOOD, 2006, 107 (05) :1892-1895
[8]   The erythropoietin receptor and its expression in tumor cells and other tissues [J].
Farrell, F ;
Lee, A .
ONCOLOGIST, 2004, 9 :18-30
[9]  
FRASER JK, 1988, BLOOD, V71, P104
[10]   THE REGULATED EXPRESSION OF ERYTHROPOIETIN BY 2 HUMAN HEPATOMA-CELL LINES [J].
GOLDBERG, MA ;
GLASS, GA ;
CUNNINGHAM, JM ;
BUNN, HF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (22) :7972-7976